[HTML][HTML] Interventional therapies for pulmonary embolism
F Götzinger, L Lauder, ASP Sharp, IM Lang… - Nature Reviews …, 2023 - nature.com
Pulmonary embolism (PE) is the leading cause of in-hospital death and the third most
frequent cause of cardiovascular death. The clinical presentation of PE is variable, and …
frequent cause of cardiovascular death. The clinical presentation of PE is variable, and …
Outcomes in high-risk pulmonary embolism patients undergoing FlowTriever mechanical thrombectomy or other contemporary therapies: results from the FLAME …
Background: Hemodynamically unstable high-risk, or massive, pulmonary embolism (PE)
has a reported in-hospital mortality of over 25%. Systemic thrombolysis is the guideline …
has a reported in-hospital mortality of over 25%. Systemic thrombolysis is the guideline …
Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials
Background The efficacy and safety of direct oral anticoagulants (DOACs) for patients with
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …
[HTML][HTML] Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
GD Barnes, A Burnett, A Allen, J Ansell… - Journal of thrombosis …, 2022 - Springer
Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …
[HTML][HTML] Meta-analysis comparing catheter-directed thrombolysis versus systemic anticoagulation alone for submassive pulmonary embolism
The optimal therapy for submassive pulmonary embolism (sPE), defined by right ventricular
dysfunction without hemodynamic instability, is uncertain. We conducted a systematic review …
dysfunction without hemodynamic instability, is uncertain. We conducted a systematic review …
[HTML][HTML] COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment
L Ortega-Paz, AH Talasaz… - … in thrombosis and …, 2022 - thieme-connect.com
COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …
Daily point-of-care ultrasound-assessment of central venous catheter-related thrombosis in critically ill patients: a prospective multicenter study
C Wu, M Zhang, W Gu, C Wang, X Zheng, J Zhang… - Intensive Care …, 2023 - Springer
Purpose Central venous catheter (CVC)-related thrombosis (CRT) is a known complication
in critically ill patients. However, its clinical significance remains unclear. The objective of the …
in critically ill patients. However, its clinical significance remains unclear. The objective of the …
Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial
W Ageno, L Bertù, E Bucherini, G Camporese… - bmj, 2022 - bmj.com
Objective To compare two different treatment durations of rivaroxaban in patients with
symptomatic isolated distal deep vein thrombosis (DVT). Design Randomised, double blind …
symptomatic isolated distal deep vein thrombosis (DVT). Design Randomised, double blind …
Venous thromboembolism in critically ill adult patients with hematologic malignancy: a population-based cohort study
Purpose The aim of this study was to describe the incidence of venous thromboembolism
(VTE) and major bleeding among hospitalized patients with hematologic malignancy …
(VTE) and major bleeding among hospitalized patients with hematologic malignancy …